Literature DB >> 33414685

Nicotine Synergizes with High-Fat Diet to Induce an Anti-Inflammatory Microenvironment to Promote Breast Tumor Growth.

Thalia Jimenez1, Theodore Friedman1,2, Jaydutt Vadgama2,3,4, Vineeta Singh1, Alexandria Tucker1, Javier Collazo1, Satyesh Sinha1,2, Amiya Sinha Hikim1,2, Rajan Singh1,3,5, Shehla Pervin1,3,5.   

Abstract

Breast cancer results from a complex interplay of genetics and environment that alters immune and inflammatory systems to promote tumorigenesis. Obesity and cigarette smoking are well-known risk factors associated breast cancer development. Nicotine known to decrease inflammatory signals also modulates immune responses that favor breast cancer development. However, the mechanisms by which nicotine and obesity contribute to breast cancer remain poorly understood. In this study, we examined potential mechanisms by which nicotine (NIC) and high-fat diet (HFD) promote growth of HCC70 and HCC1806 xenografts from African American (AA) triple negative (TN) breast cancer cells. Immunodeficient mice fed on HFD and treated with NIC generated larger HCC70 and HCC1806 tumors when compared to NIC or HFD alone. Increased xenograft growth in the presence of NIC and HFD was accompanied by higher levels of tissue-resident macrophage markers and anti-inflammatory cytokines including IL4, IL13, and IL10. We further validated the involvement of these players by in vitro and ex vivo experiments. We found a proinflammatory milieu with increased expression of IL6 and IL12 in xenografts with HFD. In addition, nicotine or nicotine plus HFD increased a subset of mammary cancer stem cells (MCSCs) and key adipose browning markers CD137 and TMEM26. Interestingly, there was upregulation of stress-induced pp38 MAPK and pERK1/2 in xenografts exposed to HFD alone or nicotine plus HFD. Scratch-wound assay showed marked reduction in proliferation/migration of nicotine and palmitate-treated breast cancer cells with mecamylamine (MEC), a nicotine acetylcholine receptor (nAchR) antagonist. Furthermore, xenograft development in immune-deficient mice, fed HFD plus nicotine, was reduced upon cotreatment with MEC and SB 203580, a pp38MAPK inhibitor. Our study demonstrates the presence of nicotine and HFD in facilitating an anti-inflammatory tumor microenvironment that influences breast tumor growth. This study also shows potential efficacy of combination therapy in obese breast cancer patients who smoke.
Copyright © 2020 Thalia Jimenez et al.

Entities:  

Year:  2020        PMID: 33414685      PMCID: PMC7752272          DOI: 10.1155/2020/5239419

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  51 in total

1.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells.

Authors:  Gabriela Dontu; Wissam M Abdallah; Jessica M Foley; Kyle W Jackson; Michael F Clarke; Mari J Kawamura; Max S Wicha
Journal:  Genes Dev       Date:  2003-05-15       Impact factor: 11.361

Review 2.  Obesity and Triple-Negative Breast Cancer: Disparities, Controversies, and Biology.

Authors:  Eric C Dietze; Tanya A Chavez; Victoria L Seewaldt
Journal:  Am J Pathol       Date:  2017-11-09       Impact factor: 4.307

3.  Increased Expression of Beige/Brown Adipose Markers from Host and Breast Cancer Cells Influence Xenograft Formation in Mice.

Authors:  Rajan Singh; Meher Parveen; John M Basgen; Sayeda Fazel; Meron F Meshesha; Easter C Thames; Brandis Moore; Luis Martinez; Carolyn B Howard; Laurent Vergnes; Karen Reue; Shehla Pervin
Journal:  Mol Cancer Res       Date:  2015-10-13       Impact factor: 5.852

Review 4.  Cigarette smoking: cancer risks, carcinogens, and mechanisms.

Authors:  Stephen S Hecht
Journal:  Langenbecks Arch Surg       Date:  2006-10-10       Impact factor: 3.445

5.  Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion.

Authors:  Béatrice Dirat; Ludivine Bochet; Marta Dabek; Danièle Daviaud; Stéphanie Dauvillier; Bilal Majed; Yuan Yuan Wang; Aline Meulle; Bernard Salles; Sophie Le Gonidec; Ignacio Garrido; Ghislaine Escourrou; Philippe Valet; Catherine Muller
Journal:  Cancer Res       Date:  2011-04-01       Impact factor: 12.701

6.  Crosstalk between nicotine and estrogen-induced estrogen receptor activation induces α9-nicotinic acetylcholine receptor expression in human breast cancer cells.

Authors:  Chia-Hwa Lee; Ya-Chieh Chang; Ching-Shyang Chen; Shih-Hsin Tu; Ying-Jan Wang; Li-Ching Chen; Yu-Jia Chang; Po-Li Wei; Hui-Wen Chang; Chien-Hsi Chang; Ching-Shui Huang; Chih-Hsiung Wu; Yuan-Soon Ho
Journal:  Breast Cancer Res Treat       Date:  2010-10-16       Impact factor: 4.872

7.  Active and passive smoking, IL6, ESR1, and breast cancer risk.

Authors:  Martha L Slattery; Karen Curtin; Anna R Giuliano; Carol Sweeney; Richard Baumgartner; Sandra Edwards; Roger K Wolff; Kathy B Baumgartner; Tim Byers
Journal:  Breast Cancer Res Treat       Date:  2007-06-27       Impact factor: 4.872

Review 8.  Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.

Authors:  Rakesh K Jain
Journal:  J Clin Oncol       Date:  2013-05-13       Impact factor: 44.544

9.  Cigarette smoke enhances initiation and progression of lung cancer by mutating Notch1/2 and dysregulating downstream signaling molecules.

Authors:  Jihong Zhou; Yuqing Chen; Wei Li; Gengyan Zhang; Peng Jiang; Lei Hong; Yuangbing Shen; Xiaojing Wang; Xiaomeng Gong
Journal:  Oncotarget       Date:  2017-11-25

10.  Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth.

Authors:  S J Werden; N Sphyris; T R Sarkar; A N Paranjape; A M LaBaff; J H Taube; B G Hollier; E Q Ramirez-Peña; R Soundararajan; P den Hollander; E Powell; G V Echeverria; N Miura; J T Chang; H Piwnica-Worms; J M Rosen; S A Mani
Journal:  Oncogene       Date:  2016-06-13       Impact factor: 9.867

View more
  1 in total

1.  Nicotine treatment regulates PD-L1 and PD-L2 expression via inhibition of Akt pathway in HER2-type breast cancer cells.

Authors:  Masanori A Murayama; Erika Takada; Kenji Takai; Nagisa Arimitsu; Jun Shimizu; Tomoko Suzuki; Noboru Suzuki
Journal:  PLoS One       Date:  2022-01-27       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.